Key result
OAC discontinuation after AF ablation shows no difference in thromboembolism but reduces major bleeding.
Why the study?
The clinical balance between residual thromboembolic risk and bleeding risk after oral anticoagulant discontinuation following atrial fibrillation ablation remains uncertain due to variable estimates from RCTs and observational studies.
Does oral anticoagulant discontinuation compared with continuation affect thromboembolic events or major bleeding in adult patients after atrial fibrillation ablation?
Meta-Analysis (n=271,808)
Does oral anticoagulant discontinuation compared with continuation affect thromboembolic events or major bleeding in adult patients after atrial fibrillation ablation?
Relative Risk: 0.93 (95% CI 0.72–1.2)
Absolute Event Rate: 1.01% vs 0.95%
p-value: p=0.58
Discontinuation of OAC after AF ablation reduces major bleeding without a statistically significant difference in thromboembolic events, supporting individualized risk-based decisions rather than routine discontinuation.
Supports risk-based OAC decisions post-AF ablation to minimize bleeding; reinforces consensus amid prior conflicting estimates.
Oral anticoagulant (OAC) therapy after atrial fibrillation (AF) ablation is recommended according to thromboembolic risk rather than procedural success alone. However, the clinical balance between residual thromboembolic risk and bleeding risk after OAC discontinuation remains uncertain because randomized controlled trials (RCTs) and observational studies have reported variable estimates. We conducted an updated systematic review and meta-analysis comparing OAC discontinuation with OAC continuation after AF ablation. Online databases were searched from inception to May 2026 for RCTs and observational studies reporting thromboembolic events, major bleeding, or all-cause mortality after post-ablation OAC discontinuation versus continuation. Random-effects Mantel-Haenszel models were used, and estimates were reported as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). Thirty-two studies comprising 271,808 patients were included, with 88,513 patients discontinuing OAC after ablation. OAC discontinuation, compared with continuation, was not associated with a statistically significant difference in thromboembolic events (RR=0.93; 95%CI=0.72 to 1.20; P=0.58; I²=53%). In contrast, OAC discontinuation significantly reduced major bleeding (RR=0.37; 95%CI=0.27 to 0.52; P<0.00001; I²=60%). No significant effect was observed for all-cause mortality (RR=0.87; 95%CI=0.70 to 1.08; P=0.22; I²=0%). In this updated systematic review and meta-analysis, OAC discontinuation after AF ablation was associated with lower major bleeding without a statistically significant difference in thromboembolic events or all-cause mortality. These findings support individualized, risk-based anticoagulation decisions among selected post-ablation patients rather than routine discontinuation. However, the very low certainty of evidence for thromboembolic outcomes, coupled with a CI that does not exclude potential harm (RR up to 1.20), underscores that these findings should not be interpreted as evidence of safety.
No takes yet. Share an insight, caveat, or question.
Cheema et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=271,808). Oral anticoagulation discontinuation vs. Oral anticoagulation continuation was evaluated on Thromboembolic events (RR 0.93, 95% CI 0.72 to 1.20, p=0.58). Oral anticoagulation discontinuation after atrial fibrillation ablation was not associated with a significant difference in thromboembolic events (RR 0.93) but significantly reduced major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: